助推生物医药产业高质量发展 成都高新区与四川发展（控股）公司签署合作协议

Group 1 - The core agreement between Chengdu High-tech Zone and Sichuan Development (Holding) Company focuses on deep cooperation in the pharmaceutical and health industry, including equity cooperation, fund establishment, talent exchange, and innovation incubation [2] - The collaboration aims to enhance the pharmaceutical health industry in Sichuan Province by building industrial funds, attracting quality projects, and developing professional incubation platforms [2][3] - Chengdu High-tech Zone is recognized as a key area for developing new productive forces, particularly in the pharmaceutical health sector, with plans to strengthen industrial cooperation in biomedicine [2] Group 2 - Since 2022, Chengdu High-tech Zone has been collaborating with Sichuan Development (Holding) Company's subsidiary, Sichuan Biopharmaceutical Group, focusing on investment in chemical drugs, medical devices, and pharmaceutical outsourcing services [3] - The partnership has successfully completed acquisitions, such as Sichuan Biopharmaceutical Group's acquisition of Hongming Bosi Pharmaceutical, and has nurtured several listed companies and local star enterprises [3] - Chengdu High-tech Zone has gathered over 3,900 biopharmaceutical companies and established more than 160 functional platforms covering the entire lifecycle of biopharmaceuticals [4] Group 3 - The capital support service system in Chengdu High-tech Zone includes a full lifecycle model with 24 pharmaceutical health funds totaling 34 billion yuan [4] - The zone has approved 12 Class I new drugs and over 100 Class III medical devices, with more than 80 products valued at over 100 million yuan [4] - Chengdu High-tech Zone has maintained a leading position in the national biopharmaceutical industrial park competitiveness ranking for several years [4]